Paper Details

  1. Home
  2. Paper Details

A novel S-nitrosocaptopril monohydrate for pulmonary arterial hypertension: H<sub>2</sub>O and -SNO intermolecular stabilization chemistry.

Author: ChenFan, ChenJianming, ChenWenge, HanLongyu, JiaLee, LiFeiyang, LinMin, ShaoJing-Wei, WangChiahung, WangJie, ZhouYuyang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

S-nitrosocaptopril (CapNO) is a drug that combines the effects of captopril and nitric oxide, potentially leading to better outcomes. A new formulation of CapNO has been developed that is more stable and may be suitable for clinical trials.
Paper Details　
Original Abstract of the Article :
S-nitrosocaptopril (CapNO) possesses dual capacities of both Captopril and an NO donor with enhanced efficacy and reduced side effects. CapNO crystals are difficult to make due to its unstable S-NO bond. Here, we report a novel stable S-nitrosocaptopril monohydrate (CapNO&#183;H<sub>2</sub>O) that i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.freeradbiomed.2018.09.020

データ提供：米国国立医学図書館（NLM）

A Novel Stable Formulation of S-nitrosocaptopril for Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH), a serious condition affecting the heart and lungs, presents a significant challenge in the field of medicine. This study delves into the potential of a novel, stable formulation of S-nitrosocaptopril (CapNO), a medication with dual therapeutic properties. CapNO acts as both an NO donor and a Captopril, offering a potential advantage in treating PAH. The researchers successfully developed a stable monohydrate form of CapNO, addressing the inherent instability of the S-NO bond. This innovative approach could pave the way for clinical trials and commercialization of a potentially effective treatment for PAH.

Exploring the Potential of a Stable CapNO Formulation

The researchers in this study have successfully developed a stable monohydrate form of S-nitrosocaptopril (CapNO). This new formulation, CapNO·H2O, shows significant promise for treating pulmonary arterial hypertension (PAH). The researchers demonstrated that CapNO·H2O is stable for an extended period, offering a more reliable and potentially effective treatment option for PAH.

The Potential Impact of Stable CapNO on PAH Treatment

This novel CapNO formulation holds the potential to revolutionize the treatment of pulmonary arterial hypertension (PAH). The researchers demonstrated the stability of CapNO·H2O, paving the way for clinical trials and potential commercialization. The results of this study offer hope for patients with PAH, who may benefit from a more effective and sustainable treatment approach.

Dr.Camel's Conclusion

The researchers in this study have bravely ventured into the harsh desert of PAH research, seeking a more stable and effective treatment. Their development of a stable monohydrate form of CapNO, CapNO·H2O, represents a significant step forward in the fight against this debilitating disease. This innovation has the potential to transform the lives of those affected by PAH, offering hope for a brighter future. Remember, my friends, even in the most challenging deserts, perseverance and innovation can lead to unexpected oases of hope.

Date :
  1. Date Completed 2019-09-30
  2. Date Revised 2019-09-30
Further Info :

Pubmed ID

30227269

DOI: Digital Object Identifier

10.1016/j.freeradbiomed.2018.09.020

Related Literature

Article Analysis
・Side Effects of captopril
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.